TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Monday

TriSalus Life Sciences (NASDAQ:TLSI) will likely be posting its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect TriSalus Life Sciences to post earnings of ($0.35) per share for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $8.26 million during the quarter, compared to analyst estimates of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $5.62 on Monday. The company’s 50-day moving average price is $5.40 and its two-hundred day moving average price is $4.73. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The stock has a market capitalization of $171.37 million, a PE ratio of -2.26 and a beta of 0.48.

Wall Street Analysts Forecast Growth

TLSI has been the topic of several analyst reports. Lake Street Capital began coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They set a “buy” rating and a $10.00 target price on the stock. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective on the stock. Roth Mkm reissued a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $11.56.

Insider Transactions at TriSalus Life Sciences

In related news, insider Sean Murphy purchased 15,000 shares of the stock in a transaction on Monday, January 27th. The shares were purchased at an average cost of $5.31 per share, with a total value of $79,650.00. Following the acquisition, the insider now directly owns 182,732 shares in the company, valued at $970,306.92. The trade was a 8.94 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Mary T. Szela acquired 5,030 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were bought at an average price of $5.03 per share, with a total value of $25,300.90. Following the completion of the transaction, the chief executive officer now directly owns 439,249 shares of the company’s stock, valued at approximately $2,209,422.47. The trade was a 1.16 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 54,856 shares of company stock worth $294,608. 32.80% of the stock is owned by company insiders.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.